A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER)
Фаза 1 – тестване на безопасността при малка група хора
Заболявания:
Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations
Спонсор: Arrivent Biopharma Inc.
Налично на:
БГ
Обобщение
Trial status: Authorised
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 32 participants
БГ
EN